Holen Sie sich die Stockscreener-App
282.85
2.26%
-6.54
Schlusskurs vom Vortag:
$289.39
Offen:
$288.96
24-Stunden-Volumen:
1.42M
Relative Volume:
1.28
Marktkapitalisierung:
$37.76B
Einnahmen:
$4.29B
Nettoeinkommen (Verlust:
$577.22M
KGV:
67.21
EPS:
4.2086
Netto-Cashflow:
$641.34M
1W Leistung:
-6.67%
1M Leistung:
-3.14%
6M Leistung:
-28.85%
1J Leistung:
-7.16%
1-Tages-Spanne:
$281.76
$291.28
1-Wochen-Bereich:
$281.76
$303.57
52-Wochen-Spanne:
$281.76
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Firmenname
Alnylam Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 551-8200
Adresse
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY vs VRTX, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
282.85 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
VRTX
Vertex Pharmaceuticals Inc
|
444.93 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.14 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
893.52 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
153.87 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Herabstufung | Jefferies | Buy → Hold |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2026-01-07 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-08-04 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Fortgesetzt | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-16 | Hochstufung | Goldman | Neutral → Buy |
| 2024-02-16 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-10-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-05-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-06-07 | Eingeleitet | William Blair | Outperform |
| 2022-04-25 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Eingeleitet | Citigroup | Buy |
| 2022-02-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-01-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Hochstufung | Goldman | Neutral → Buy |
| 2021-11-22 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-08-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-02-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-02-12 | Bestätigt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Fortgesetzt | Berenberg | Hold |
| 2020-09-08 | Eingeleitet | Citigroup | Buy |
| 2020-08-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-03-19 | Eingeleitet | Berenberg | Buy |
| 2019-12-19 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-11-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Bestätigt | Stifel | Buy |
| 2018-08-07 | Hochstufung | Stifel | Hold → Buy |
| 2018-05-04 | Bestätigt | Stifel | Hold |
| 2018-03-28 | Eingeleitet | Evercore ISI | In-line |
Alle ansehen
Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten
Alnylam Pharmaceuticals stock hits 52-week low at $282.71 By Investing.com - Investing.com Australia
Alnylam Pharmaceuticals stock hits 52-week low at $282.71 - Investing.com
Alnylam to Host Tenth “RNAi Roundtable” Webcast Series - BioSpace
Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum? - The Globe and Mail
Andra AP fonden Grows Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
What Does the Alnylam-Inceptive AI Deal Entail - Kavout
Motley Fool Asset Management LLC Purchases 3,480 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
GENESIS Pharma Broadens Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics Across Nordic Markets - World Business Outlook
Alnylam Pharmaceuticals unveils 2030 targets, betting on AMVUTTRA and pipeline readouts - MSN
A Look At Alnylam Pharmaceuticals (ALNY) Valuation As 2030 Goals And AI Partnership Refocus Growth Expectations - simplywall.st
Genesis and Alnylam Expand Partnership to Commercialize RNAi Therapeutics for Nordic Region - Contract Pharma
Alnylam Stock Is Running Its Own Race. Here’s What That Means for Your Portfolio. - Trefis
Alnylam expands Genesis Pharma collaboration in Europe - MSN
Alnylam expands Genesis Pharma deal in Europe (ALNY:NASDAQ) - Seeking Alpha
Genesis Pharma expands Alnylam partnership to Nordic markets - Investing.com
Genesis Pharma expands Alnylam partnership to Nordic markets By Investing.com - Investing.com South Africa
Junevity Partners with Sunrise BioVentures as Advisors to Accelerate siRNA Therapeutic Development - Business Wire
GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region - Stock Titan
Alnylam Stock Is Running Its Own Race. Here's What That Means for Your Portfolio. - Trefis
Alnylam Pharmaceuticals Unveils 2030 Targets, Betting on AMVUTTRA and Pipeline Readouts - Yahoo Finance
Fiera Capital Corp Purchases 16,916 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam to collaborate with Inceptive to use AI for RNAi therapy development - MSN
Alnylam Slides as Investors Refocus on Near-term Amvuttra Growth After Recent AI-deal Headlines - Moomoo
Bloom Energy, Astera Labs, Alnylam, Reddit could be among next adds to S&P 500 - MSN
Bloom Energy, Astera Labs, Alnylam, Reddit Could Be Among Next Adds to S&P 500 - Barron's
City banks nearly $100M for next-gen RNAi drugs - BioPharma Dive
Alnylam Pharmaceuticals (NASDAQ:ALNY) Shares Down 5%What's Next? - MarketBeat
Alnylam slides as investors refocus on near-term Amvuttra growth after recent AI-deal headlines - Quiver Quantitative
Capital International Inc. CA Sells 16,086 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Shares Acquired by BI Asset Management Fondsmaeglerselskab A S - MarketBeat
ALNY News | ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) - ChartMill
Regeneron: 'Buy' Revenue Growth And Two Extensive Drug Development Opportunities - Seeking Alpha
Los Angeles Capital Management LLC Buys 80,658 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
The week in pharma: action, reaction and insight – week to June 5, 2026 - The Pharma Letter
Capital Research Global Investors Reduces Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Capital World Investors - MarketBeat
Capital International Ltd. CA Sells 10,556 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Capital International Sarl Has $47.46 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Westfield Capital Management Co. LP Acquires 5,536 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Savant Capital LLC Sells 5,677 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Bank of New York Mellon Corp Lowers Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
CIBC Asset Management Inc Increases Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
How a US$2 Billion Generative AI RNAi Deal At Alnylam Pharmaceuticals (ALNY) Has Changed Its Investment Story - simplywall.st
H.C. Wainwright reiterates Alnylam stock Buy rating at $510 By Investing.com - Investing.com Canada
Alnylam Pharmaceuticals (ALNY) Valuation Check As US$2b AI RNAi Collaboration With Inceptive Nucleics Gains Attention - Yahoo Finance
Harvest Fund Management Co. Ltd Has $4.10 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (ALNY) Partners with Inceptive Nucleics to Enhance Drug Discovery - GuruFocus
ALNY Reiterated by HC Wainwright & Co. -- Maintains Price Target at $510 - GuruFocus
Ionis, Alnylam, BioMarin up as Citi starts at buy on catalyst and growth outlook - MSN
H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $510 - Moomoo
Alnylam Eyes Faster Drug Discovery With AI Partnership Worth Up To $2 Billion - Benzinga
Finanzdaten der Alnylam Pharmaceuticals Inc-Aktie (ALNY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alnylam Pharmaceuticals Inc-Aktie (ALNY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| PYOTT DAVID E I | Director |
Jun 01 '26 |
Sale |
299.18 |
3,830 |
1,145,853 |
1,582 |
3.11%
0.76%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):